Insulin resistance as an independent predictor of metabolic dysfunction-associated steatohepatitis (MASH) severity: combined data from multiple therapeutic trials including more than 10, 000 patients

被引：0
|
作者：
Ratziu, Vlad [1 ]
Schattenberg, Jorn M. [2 ]
Alkhouri, Naim
Noureddin, Mazen [3 ,4 ]
Charlton, Michael [5 ]
Dubourg, Julie [6 ]
Harrison, Stephen A. [7 ]
机构：
[1] Sorbonne Univ, Inst Cardiometabolism & Nutr, Hosp Pitie Salpetriere, INSERM,UMRS 1138 CRC, Paris, France
[2] Saarland Univ, Med Ctr, Homburg, Germany
[3] Arizona Liver Hlth, Phoenix, AZ USA
[4] Houston Res Inst, Houston, TX USA
[5] Univ Chicago, Chicago, IL USA
[6] Summit Clin Res, San Antonio, TX USA
[7] Summit Clin Res, San Antonio, TX USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
FRI-199
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 30 条
  • [21] Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
    Alkhouri, Naim
    Dubourg, Julie
    Harrison, Stephen
    Charlton, Michael
    Ratziu, Vlad
    Schattenberg, Jorn
    Megnien, Sophie Jeannin
    Noureddin, Mazen
    JOURNAL OF HEPATOLOGY, 2023, 78 : S31 - S31
  • [22] LIVER HISTOLOGY OVERESTIMATES STEATOSIS IN PRESENCE OF ADVANCED FIBROSIS: COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS ( IN COLLABORATION WITH NAIL- NIT CONSORTIUM)
    Noureddin, Mazen
    Dubourg, Julie
    Jeannin, Sophie
    Alkhouri, Naim
    Schattenberg, Joern M.
    Harrison, Stephen A.
    HEPATOLOGY, 2023, 78 : S820 - S824
  • [23] How many real world patients diagnosed with metabolic dysfunction-associated steatohepatitis meet clinical trial eligibility criteria? Findings from a large cohort study of more than 18, 000 patients from the United States
    Schattenberg, Joern M.
    Sartini, Claudio
    Herrera, Ronald
    Raluy, Mireia
    Yates, Mark
    Younes, Ramy
    JOURNAL OF HEPATOLOGY, 2024, 80 : S509 - S510
  • [24] Causes of Death, Mortality Rates, and the Role of Socio-Demographic Risk Factors and Biomarkers in Metabolic Dysfunction-Associated Steatohepatitis Mortality in More Than 18,000 Real World Patients From the United States
    Schattenberg, Joern M.
    Sartini, Claudio
    Herrera, Ronald
    Raluy, Mireia
    Yates, Mark
    Younes, Ramy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1308 - S1308
  • [25] Performance of non-invasive tests as exclusion criteria for cirrhosis in trials targeting at-risk non-alcoholic steatohepatitis: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
    Alkhouri, Naim
    Dubourg, Julie
    Harrison, Stephen
    Noureddin, Mazen
    Charlton, Michael
    Ratziu, Vlad
    Megnien, Sophie Jeannin
    Schattenberg, Joern
    JOURNAL OF HEPATOLOGY, 2023, 78 : S655 - S656
  • [26] Diagnosed prevalence of cardio-renal diseases, mental health disorders, sleep apnea, cancer, and mortality rates in more than 18, 000 patients with metabolic dysfunction-associated steatohepatitis with and without cirrhosis from the United States
    Schattenberg, Joern M.
    Sartini, Claudio
    Herrera, Ronald
    Raluy, Mireia
    Yates, Mark
    Younes, Ramy
    JOURNAL OF HEPATOLOGY, 2024, 80 : S486 - S486
  • [27] Performance of vibration controlled transient elastography and related scores to identify at-risk non-alcoholic steatohepatitis patients: combined data from multiple trials including more than 5,000 patients (in collaboration with NAIL-NIT consortium)
    Noureddin, Mazen
    Dubourg, Julie
    Harrison, Stephen
    Megnien, Sophie Jeannin
    Ratziu, Vlad
    Charlton, Michael
    Alkhouri, Naim
    Schattenberg, Jorn
    JOURNAL OF HEPATOLOGY, 2023, 78 : S31 - S32
  • [28] Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)
    Schattenberg, Jorn
    Dubourg, Julie
    Noureddin, Mazen
    Alkhouri, Naim
    Ratziu, Vlad
    Charlton, Michael
    Megnien, Sophie Jeannin
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2023, 78 : S604 - S605
  • [29] GLYCEMIC CONTROL IMPACTS FIB-4 PERFORMANCE TO PREDICT ADVANCED FIBROSIS AND IS INDEPENDENTLY ASSOCIATED WITH THE PRESENCE OF HEPATOCYTE BALLOONING: COMBINED DATA FROM MULTIPLE THERAPEUTIC TRIALS INCLUDING MORE THAN 6,000 PATIENTS ( IN COLLABORATION WITH NAIL- NIT CONSORTIUM)
    Harrison, Stephen A.
    Dubourg, Julie
    Jeannin, Sophie
    Alkhouri, Naim
    Noureddin, Mazen
    Schattenberg, Joern M.
    HEPATOLOGY, 2023, 78 : S802 - S806
  • [30] The impact of glycemic control on progressive forms of non-alcoholic fatty liver disease: combined data from multiple clinical trials including more than 5000 patients (in collaboration with NAIL-NIT consortium)
    Noureddin, Mazen
    Dubourg, Julie
    Schattenberg, Joern
    Charlton, Michael
    Harrison, Stephen
    Alkhouri, Naim
    Megnien, Sophie Jeannin
    Ratziu, Vlad
    JOURNAL OF HEPATOLOGY, 2023, 78 : S619 - S619
123